- Home
- BTAI vs ICMB Comparison
BTAI vs ICMB Comparison
Compare BTAI & ICMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTAI | ICMB |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.7M | 38.8M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | BTAI | ICMB |
|---|---|---|
| Price | $1.80 | $2.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $26.67 | N/A |
| AVG Volume (30 Days) | ★ 644.4K | 22.0K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | ★ 18.64% |
| EPS Growth | N/A | ★ 31.51 |
| EPS | N/A | ★ 0.38 |
| Revenue | $752,000.00 | ★ $17,931,778.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $265.60 | $4.75 |
| P/E Ratio | ★ N/A | $7.28 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.17 | $2.46 |
| 52 Week High | $8.08 | $3.47 |
Technical Indicators
Market Signals| Indicator | BTAI | ICMB |
|---|---|---|
| Relative Strength Index (RSI) | 45.04 | 53.94 |
| Support Level | $1.85 | $2.75 |
| Resistance Level | $2.08 | $2.89 |
| Average True Range (ATR) | 0.15 | 0.06 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 38.57 | 65.22 |
Price Performance
Historical ComparisonAbout BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About ICMB Investcorp Credit Management BDC Inc.
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). Its investment objective is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.